HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected to be $265 - $280 million Cash position increased to $742 million at year end and expect to be cash flow positive for full year 2024 Conference call today at 4:30 p.m. ET/1:30 p.m. PT  EMERYVILLE, Calif., Feb. 22, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or other juris ...

EMERYVILLE, Calif., Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT.The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.c ...

libre de droit Facts are threatening to those invested in fraud.”― DaShanne Stokes. Today, we put Dynavax Technologies Corporation (NASDAQ:DVAX) in the spotlight as 2024 commences. This is a name that has been a rock-solid covered call holding within my portfolio for several years. The company got a burst a revenue from the Covid pandemic, which has now all but completely dissipated. However, this bounty helped the company bolster its cash reserves, establish itself as the standard of care in the hepati ...

Forward-Looking Statements © Copyright DYNAVAX 2023 2 | Q3 2023 Business Highlights Ryan Spencer Chief Executive Officer Clinical Pipeline Update Robert Janssen Chief Medical Officer Q&A Session Dynavax Core Strategic Priorities • Increase market share to become the market leader by 2027 • Deliver on our innovative and diversified pipeline leveraging CpG 1018® adjuvant with proven antigens | --- | --- | |--------------------|-------| | | | | | | | Identify Strategic | | | Opportunities to | | | Accelerate G ...

Start Time: 16:30 January 1, 0000 4:59 PM ET Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2023 Earnings Conference Call November 02, 2023, 16:30 PM ET Company Participants Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Paul Cox - VP of IR and Corporate Communications Conference Call Participants Matthew Phipps - William Blair Ernesto Rodriguez-Dumont - TD Cowen Jonathan Miller - Evercore ISI Roy Buchanan - JMP Securities Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Paul Cox - VP of IR and Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Ernesto Rodriguez-Dumont - TD Cowen Roy Buchanan - JMP Securities Jonathan Miller - Evercore ISI Operator Good day ladies and gentlemen, and welcome to Dynavax ...

| --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------|-------|-------|-----------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Second Quarter 2023 Financial Results | | | | | | | | | | | | Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases | | | | | | | | | August 3, 2023 Nasdaq: DVAX | | Statements contained in this presentation regard ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or ot ...